INV-2341

INV-2341 is an orally bioavailable small molecule inhibitor of Interleukin-17 (IL-17) currently in preclinical development by Ionova Life Sciences. As a small molecule alternative to established injectable monoclonal antibodies, INV-2341 is designed to provide a more convenient therapeutic option for patients suffering from various autoimmune and inflammatory diseases. The drug's mechanism involves the targeted disruption of IL-17 signaling, a key driver in the pathogenesis of conditions such as psoriasis, rheumatoid arthritis, and ankylosing spondylitis. By inhibiting this pro-inflammatory cytokine, INV-2341 aims to suppress the downstream inflammatory cascade and alleviate disease symptoms.